We are live on ! Find out more
AXN

Aoxing Pharmaceutical
AXN

Delisted

AXN was delisted on the 16th of October, 2017.

14 hedge funds and large institutions have $262K invested in Aoxing Pharmaceutical in 2015 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

40% more funds holding

Funds holding: 10 → 14 (+4)

2.89% less ownership

Funds ownership: 3.41% → 0.52% (-2.9%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

94% less capital inflows, than outflows

Capital inflows: $198K | Capital outflows: $3.18M

Holders
14
Holders Change
+4
Holders Change %
+40%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

AXN Hedge Fund Activity: Q4 2015 in Review

14 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Aoxing Pharmaceutical (AXN) for Q4 2015, worth a combined $262K — down 93% from $3.53M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new AXN positions and 3 closed out — a net gain of 4 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Bank of New York Mellon, opening a new position worth an estimated $65.6K. The largest seller was Sabby Management, exiting entirely with an estimated $3.16M sold.

  • 14 institutional investors held Aoxing Pharmaceutical (AXN) as of Q4 2015, up from 10 in Q3 2015.
  • Funds reported $262K of Aoxing Pharmaceutical stock for Q4 2015, down 93% quarter-over-quarter.
  • 7 funds opened new Aoxing Pharmaceutical positions in Q4 2015 and 3 closed out, a net change of +4 holders.
  • The largest Aoxing Pharmaceutical buyer in Q4 2015 was Bank of New York Mellon, an estimated $65.6K added.
  • The largest Aoxing Pharmaceutical seller in Q4 2015 was Sabby Management, an estimated $3.16M sold.

Based on aggregated 13F filings for Q4 2015.